Articles & Video
Survey: Antibody Engineering & Therapeutics State of the Industry 2021
What has changed in antibody engineering and antibody-based therapeutics over the last year? Tell us your experience in our industry survey.
eBook: Antibody Discovery, Selection & Screening
This ebook uncovers the latest approaches and emerging tools for therapeutic antibody discovery.
Human Monoclonal Antibodies for SARS-CoV-2
We look at single cell technologies for the isolation of human monoclonals, the molecular basis for SARS-CoV-2 neutralization and antibody synergistic exploration.
REPORT: Diversity, Equity and Inclusion in the Life Sciences 2021
Explore the Diversity, Equity and Inclusion in the Life Sciences 2021 report based on an exclusive study of 483 industry professionals.
Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days - WEBINAR
We look at how neutralizing antibodies against COVID-19 were rapidly discovered, characterized and screened to identify potential drug candidates.
Developments in ADC Technology: Toxicity and Design Strategies
We examine the latest developments in ADC technology, as discussed by industry leaders at the Antibody Engineering & Therapeutics conference.
Novel Non-cancer Targets for Therapeutic Antibodies
We look at the latest work on developing non-cancer targets for therapeutic antibodies discussed by industry leaders at Antibody Engineering & Therapeutics.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
Post-event Report: Antibody Engineering & Therapeutics Virtual 2020
We look back at highlights of the recent Antibody Engineering & Therapeutics virtual conference.
BioProcess International 2020 Post-Event Report
Explore the highlights of the BioProcess International 2020 virtual conference in the post-event round-up.
Novel Antibody Therapeutic Modalities - Antibody Therapeutics eBook Series
We take an in-depth look at the novel antibody therapeutic modalities being developed and how they are tackling new non-cancer targets in this Antibody Therapeutics eBook.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
Post-Event Report: Antibody Engineering and Therapeutics Europe 2020
Explore the highlights of Antibody Engineering & Therapeutics Europe Virtual 2020 in this post-event report.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Diversity and Inclusion in Biotech
The life science industry has a challenge to become more equal, diverse and inclusive. Join us at Diversity and Inclusion in Biotech, September 22nd and find out how TOGETHER we can make a difference.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
42% of pharma industry believe cell and gene therapies to be most promising therapeutics
According to a recent study, 42% of pharma industry professionals predict cell and gene therapies are the therapeutic area that will see the fastest growth in the next 10 years.
80% of life sciences professionals predict a COVID-19 vaccine will be approved within 18 months
How quickly to life sciences professionals predict a COVID-19 vaccine will be approved and what are the main obstacles? We explore.
Podcast: How to Create the Ultimate Bispecific
What goes into making the perfect bispecific? In our first Life Sciences podcast, we find out the best steps from Volker Schellenberger at Amunix.
The biggest breakthroughs in life sciences the last 10 years
CRISPR, CAR-T, immunotherapies, genome sequencing, AI - what is the biggest breakthrough in the life sciences in the last 10 years?
Strategies to Innovate the Production of Next Generation Bioconjugates
From developing ADCs to tumor-targeting, this whitepaper reviews the latest common challenges and novel strategies for producing bioconjugates.